RFK, Jr. just claimed the keto diet can cure schizophrenia. Here’s what the science says

HHS Secretary Robert F. Kennedy Jr. promoted new nutrition guidance favoring red meat, whole milk and animal fats and claimed a ketogenic diet can cure schizophrenia and bipolar disorder, assertions experts call misleading and unsupported by the evidence. Researchers such as Christopher Palmer note small pilot studies suggest possible symptom improvement for some individuals, but antipsychotics remain the frontline treatment and randomized controlled trials for keto in schizophrenia have just completed with results pending. The comments raise reputational and regulatory questions but contain no decisive clinical or market-moving data at this time.

Analysis

Market Structure: Short-term winners are specialty medical-nutrition suppliers, CPG brands marketing ‘keto’ products, and US meat/dairy processors (modest upside to TSN-level producers) as retail search/data typically drives a 4–12 week sales uplift; losers are niche plant-based challengers and unbranded commodity processors if demand shifts. Competitive dynamics favor vertically integrated food processors and branded clinical-nutrition players that can command 10–30% premium pricing for clinician-prescribed formulas; small-cap suppliers could see >50% intrayear swings on trial headlines. Cross-asset: expect small positive pressure on live-cattle/dairy commodity prices (1–3% move), higher idiosyncratic equity vol in nutrition/biotech names, and negligible sovereign-bond impact unless policy shifts broaden.

Risk Assessment: Tail risks include (1) both RCTs negative → 30–70% drawdown in small clinical-nutrition names; (2) FDA enforcement against therapeutic claims → regulatory fines and delisting risk; (3) political/regulatory reversal at HHS → reputational contagion. Timeframes: immediate (days) = retail/PR volatility; short-term (weeks–months) = sales data and search trends; long-term (6–24 months) = RCT publications and reimbursement decisions that determine durable TAM. Hidden dependencies: clinician adoption, payer reimbursement, and supply of specialty ingredients (MCT oil/coconut derivatives) are binary amplifiers. Key catalysts: RCT publications (next 12 months), HHS guidance memos, FDA warning letters.

Key Decisions for Investors

• Establish a tactical 1–2% long position in Abbott Laboratories (ABT) to capture medical-nutrition upside; implement a 3–6 month call-spread (buy 5% OTM, sell 15% OTM) sized to 1% portfolio risk, take profit +30% or cut at -20%.
• Allocate 0.5–1% long to Tyson Foods (TSN) via outright equity or 3-month ATM calls to play incremental red-meat demand; pair with a 0.5% short in Beyond Meat (BYND) to capture relative share loss if animal-meat sentiment inflects.
• Buy 0.5–1% long in XLV (healthcare ETF) to capture re-rating if RCTs read positive; hedge with a 6–12 month 2% portfolio put protection if both trials are published negative within 12 months (defined as failing primary endpoint).
• If either randomized trial publishes a positive primary endpoint within 12 months, increase exposure to small-cap clinical-nutrition suppliers by an additional 3–5% (names to pick when liquidity/financials checked); conversely, if both trials negative or FDA issues enforcement within 90 days, liquidate related positions and reallocate to consumer staples staples (-allocate to XLP).
• Monitor within 30 days: HHS internal guidance or FDA enforcement letters and weekly retail sales/search volumes (Nielsen/IRI + Google Trends). Use a trigger: >15% sequential weekly sales lift for branded ketogenic formulas to scale positions up by 50% of targeted sizing.